Signaling network inference for cance subtipes

$484,919U54FY2014CANIH

Oregon Health & Science University, Portland OR

Investigators

Linked publications, trials & patents

Paper 34211050 Paper 30856168 Paper 30232459 Paper 30214939 Paper 29760043 Paper 29560860 Paper 29112189 Paper 28958991 Paper 28725457 Paper 28487443 Paper 28191459 Paper 28167613 Paper 28087598 Paper 28017544 Paper 27990101 Paper 27913436 Paper 27669434 Paper 27663479 Paper 27605183 Paper 27581127 Paper 27368372 Paper 27356755 Paper 26901648 Paper 26894975 Paper 26779250 Paper 26661596 Paper 26526695 Paper 26516700 Paper 26513549 Paper 26505200 Paper 26438156 Paper 26423697 Paper 26389641 Paper 26343386 Paper 26286987 Paper 26251290 Paper 26248648 Paper 26181325 Paper 26097445 Paper 26080442 Paper 25901353 Paper 25896888 Paper 25681694 Paper 25681442 Paper 25639871 Paper 25619841 Paper 25495633 Paper 25490449 Paper 25419740 Paper 25378249 Paper 25284480 Paper 25212499 Paper 25161235 Paper 25157401 Paper 25109877 Paper 24880487 Paper 24871328 Paper 24868026 Paper 24719451 Paper 24656791 Paper 24642504 Paper 24630040 Paper 24583248 Paper 24511382 Paper 24492837 Paper 24412474 Paper 24395801 Paper 24243820 Paper 24224142 Paper 24213538 Paper 24176112 Paper 24158481 Paper 24094812 Paper 24067649 Paper 24055055 Paper 23929892 Paper 23918833 Paper 23912456 Paper 23867473 Paper 23629662 Paper 23592797 Paper 23584089 Paper 23577104 Paper 23400595 Paper 23389994 Paper 23284978 Paper 23284600 Paper 23251624 Paper 23250208 Paper 23219535 Paper 23210478 Paper 23129656 Paper 23110523 Paper 23097110 Paper 23097109 Paper 22969158 Paper 22965149 Paper 22923301 Paper 22886303 Paper 22875744

Abstract

Breast tumors display remarkable biological and clinical heterogeneity as covered extensively in the Introduction and Progress Report. Developing a better understanding of the molecular basis of such heterogeneity is central to the goal of rational, individualized treatment for patients based on molecular profiling. A large number of pathways, including RTKs, RAF/MEK/ERK, AKT, NFKB, JAK/STAT, JNK, p38, etc. work to control diverse cellular processes. In cancer the aberrant activity of the system is responsible for proliferation, apoptosis and other hallmarks of cancer. Diverse open questions concerning both the basic biology of cancer signaling and related therapeutic implications are rooted in tumor-specific network connectivity. The need to elucidate such tumor specific connectivity motivates the broad goals of this project.

View original record on NIH RePORTER →